The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM
The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of Gastric or Esophagogastric Junctional Cancer With Peritoneal Metastasis: A Prospective, Multicenter Phase II Study
Sponsor: The First Affiliated Hospital with Nanjing Medical University
A PHASE2 clinical study on Gastric Cancer, Metastatic, this trial is ongoing. The trial is conducted by The First Affiliated Hospital with Nanjing Medical University and has accumulated 4 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Aug 2025 — Present [monthly]
Active Not Recruiting PHASE2
Status: Not Yet Recruiting → Active Not Recruiting
-
Sep 2024 — Aug 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
May 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The First Affiliated Hospital with Nanjing Medical University
For direct contact, visit the study record on ClinicalTrials.gov .